Beneficiary

Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto)

Porto,

Portugal

The Portuguese Oncology Institute of Porto (IPO Porto) is a highly differentiated organisation belonging to the National Health System and providing specialised care. IPO Porto is a national and international reference health institution in oncological treatment, research and education. IPO PORTO is accredited as a Comprehensicve Cancer Center by the European Organization of Cancer Institutes (OECI).

IPO PORTO is involved in serveral project activities, including WP 1 (data aggregation), WP3 (expansion cohorts) and WP6 (social innovation).

Key People Involved:

Julio Oliveira

MD, Medical Oncologist and Clinical Pharmacologist, President of the board of IPO-Porto

Professor Henrique Rui

MD PhD, Pathologist, Director of Pathology Department of IPO Porto

Beatrice Mainoli

MD, Clinical Pharmacologist, Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto)

Joana Assis

PhD, Clinical Research Coordinator, Early Phase Clinical Trial Unit, IPO Porto

partners

Beneficiaries & Associated Partners

Associated Partner

National Cancer Institute (NVI)

Participation in WP1 (data aggregation), WP3 (expansion cohorts) and WP6 (social innovation).

Beneficiary

Helsinki University Hospital (HUS)

Work package leader dissemination (WP8). Will in addition contribute to WP1 (data aggregation), WP3 (expansion cohorts) and WP6 (social innovation).

Associated Partner

Heidelberg University Hospital

Participation in WP1 (data aggregation), WP3 (expansion cohorts) and WP6 (social innovation).